Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11

Journal of Infectious Diseases

Volumn 189, Issue 5, 2004, Pages 871-879

  Vambutas, Andrea ^a,b   Bonagura, Vincent R ^a,b   Reed, Elaine F ^c   Abramson, Allan L ^b   Mullooly, Virginia ^b   Devoti, James ^a,b   Gjertson, David W ^c   Steinberg, Bettie M ^a,b  

^a N Shore Long Isl Jewish Res Inst ^*  (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HLA ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CHROMOSOME 6; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PAPILLOMATOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; WART VIRUS;

ATP-BINDING CASSETTE TRANSPORTERS; CHROMOSOMES, HUMAN, PAIR 6; HLA-D ANTIGENS; HLA-DR ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 1542327557     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381764     Document Type: Article

References (59)

1. Gissman L, Diehl V, Schultz-Coulon JH, zur Hausen H. Molecular cloning and characterization of human papillomavirus DNA derived from a laryngeal papilloma. J Virol 1982; 44:393-400.
2. Mounts P, Shaw KV, Kashima H. Viral etiology of juvenile and adult onset squamous papilloma of the larynx. Proc Natl Acad Sci USA 1982; 79:5425-9.
3. Abramson AL, Steinberg BM, Winkler B. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 1987; 97: 678-85.
4. Armstrong LR, Preston EJ, Reichert M, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000; 31:107-9.
5. Bonagura VB, Siegal FP, Abramson AL, et al. Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin Diagn Lab Immunol 1994; 1:357-60.
6. Haglund S, Lundquist PG, Cantell K, et al. Interferon therapy in juvenile laryngeal papillomatosis. Arch Otolaryngol 1981; 107:327-32.
7. Steinberg BM, Gallagher T, Stoler M, Abramson AL. Persistence and expression of human papillomavirus during interferon therapy. Arch Otolaryngol Head Neck Surg 1988; 114:27-32.
8. +-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release. J Virol 2002; 76:6027-36.
9. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23:255-66.
10. Vambutas A, Bonagura VR, Steinberg BM. Altered expression of TAP-1 and major histocompatibility complex class 1 in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin Diagn Lab Immunol 2000; 7:79-85.
11. Doan T, Herd K, Street M, et al. Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human and mouse major histocompatibility complex class I alleles. J Virol 1999; 73:6166-70.
12. + T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin 14 promoter. J Virol 2001; 75: 5985-97.
13. Vierboom MP, Feltkamp MC, Neisig A, et al. Peptide vaccination with an anchor-replaced CTL epitope protects against human papilloma-virus type 16-induced tumors expressing the wild-type epitope. J Immunother 1998; 21:399-408.
14. Spies T, Cerundolo V, Colonna M, Cresswell P, Townsend A, DeMars R. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature 1992; 355:644-6.
15. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumors on. Immunol Today 1997; 18:292-9.
16. Kallfelz M, Jung D, Hilmes C, et al. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP-1 gene transfer. Int J Cancer 1999; 81:125-33.
17. Cromme FV, Airey J, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
18. Vos JC, Spee P, Momburg F, Neefjes J. Membrane topology and dimerization of the two subunits of the transporter associated with antigen processing reveal a three-domain structure. J Immunol 1999; 163: 6679-85.
19. Nijenhuis M, Schmitt S, Armandola EA, Obst R, Brunner J, Hammerling GJ. Identification of a contact region for peptide on TAP1 chain of the transporter associated with antigen processing. J Immunol 1996; 156:2186-95.
20. Gaudet R, Wiley DC. Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing. EMBO J 2001; 20:4964-72.
21. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 1992; 89:3932-6.
22. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 1993; 37:266-73.
23. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 1993; 37:373-80.
24. Chou PY, Fasman GD. Conformational parameters for amino acids in helical, β-sheet, and random coil regions calculated from proteins. Biochemistry 1974; 13:211-22.
25. Fruh K, Ahn K, Djaballah H, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375:415-8.
26. Hengel H, Koopmann JO, Flohr T, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997; 6:623-32.
27. Hill A, Jugovic P, York I, et al. Herpes simplex turns off the TAP to evade host immunity. Nature 1995; 375:411-5.
28. Beck S, Belich M, Gruneberg U, et al. Organisation and functions of class II genes and molecules. DNA Seq 1996; 7:21-3.
29. Kuzushita N, Hayashi N, Kanto T, et al. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infections. Gastroenterology 1999; 116:1149-54.
30. Akuta N, Chayama K, Suzuki F, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2 (TAP2)*0201 allele. J Med Virol 2001; 64:109-16.
31. Sugimoto Y, Kuzushita N, Takehara T, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9:377-84.
32. Rajalingham R, Singal DP, Mehra NK. Transporter associated with antigen-processing (TAP) genes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis. Tissue Antigens 1997; 49:168-72.
33. Hayney MS, Poland GA, Dimanlig P, Schaid DJ, Jacobson RM, Lipsky JJ. Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 1997; 15:3-6.
34. Liu C, Carrington M, Kaslow RA, et al. Association of polymorphisms in human leukocyte antigen class and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187:1404-10.
35. Gostout BS, Poland GA, Calhoun ES, et al. TAP1, TAP2 and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003; 88: 326-32.
36. Abramson AL, Shikowitz MJ, Mullooly VM, Steinberg BM, Amella CA, Rothstein HR. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1992; 118:25-9.
37. Maran A, Amella CA, DiLorenzo TP, Auborn KJ, Taichman LB, Steinberg BM. Human papillomavirus type 11 transcripts are present in low abundance in latently infected respiratory tissues. Virology 1995; 212: 285-94.
38. van Endert PM, Lopez MT, Pastel SD, Monaco JJ, McDevitt HO. Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc Natl Acad Sci USA 1992; 89:11594-7.
39. Jackson DG, Capra JD. TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility. Proc Natl Acad Sci USA 1993; 90:11079-83.
40. Sayer D, Whidborne R, Brestovac B, Trimboli F, Witt C, Christiansen F. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens 2001; 57:46-54.
41. Tilanus MGJ, ed. IHWG technical manual: genomic analysis of the human MHC: DNA-based typing for HLA alleles and linked polymorphisms. Seattle: International Histocompatiblity Working Group, 2003. Available at: http://www.ihwg.org/shared/tm2.htm. Accessed 9 February 2004.
42. Levinson RD, Park MS, Rikkers SM, et al. Strong associations between specific HLA-DR and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 2003; 44:653-7.
43. Reed E, Ho E, Lupu F, et al. Polymorphism of HLA in the Romanian population. Tissue Antigens 1992; 39:8-13.
44. White H. A heteroskedasticity-consistent covariance estimator and a direct test for heteroskedasticity. Econometrica 1980; 48:817-38.
45. Pollack MS, Levine LS, O'Neill GJ, et al. HLA linkage and B14, DR1, BfS haplotypes association with the genes for late onset and cryptic 21-hydroxlase deficiency. Am J Hum Genet 1981; 33:540-50.
46. Gelder CM, Martin Williams O, Hart KW, et al. HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis. J Virol 2003; 77:1927-39.
47. Madeleine MM, Brumback B, Cushing-Haugen KL, et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002; 186:1565-74.
48. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJW, Kitchner HC, Stern PL. Association between human leukocytic antigen polymorphism and human papillomavirus 16-positive vulvar intraepithelial neoplasia in British women. Cancer Res 2003; 63:400-3.
49. Gao XJ, Moraes JR, Miller S, Stastny P. DNA typing for class II HLA antigens with allele specific or group specific amplification. V. Typing for subsets of HLA-DR1 and DR'Br'. Hum Immunol 1991; 30:147-54.
50. Rowland-Jones SL, Powis SH, Sutton J, et al. An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. Eur J Immunol 1993; 23:1999-2004.
51. Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocytic antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis 2002; 186:164-72.
52. Kleijmeer MJ, Kelly A, Geuze HJ, Slot JW, Townsend A, Trowsdale J. Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature 1992; 357:342-4.
53. Neefjes JJ, Momberg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993; 261:769-71.
54. Saveanu L, Daniel S, van Endert PM. Distinct functions of the ATP binding cassettes of transporters associated with antigen processing. J Biol Chem 2001; 276:22107-13.
55. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha-and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982; 1:945-51.
56. Schneider E, Hunke S. ATP-binding cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol Rev 1998; 22:1-20.
57. Daniel S, Caillat-Zucman S, Hammer J, Bach JF, van Endert PM. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 1997; 159:2350-7.
58. Quadri SA, Singal DP. Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol Lett 1998; 61:25-31.
59. Vambutas A, DeVoti J, Pinn W, Steinberg BM, Bonagura VR. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in a reduction of ATP-dependent peptide transport. Clin Immunol 2001; 101:94-9.